CA2145605A1 - Modulation de l'activite cellulaire - Google Patents

Modulation de l'activite cellulaire

Info

Publication number: CA2145605A1
Authority: CA; Canada
Prior art keywords: hyaluronic acid; daltons; human; agent; molecular weight
Prior art date: 1995-03-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA 2145605

Other languages

English (en)

Inventor

Samuel Simon Asculai

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Hyal Pharmaceutical Corp

Original Assignee

Hyal Pharmaceutical Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-03-27

Filing date

1995-03-27

Publication date

1996-09-28

1995-03-27 Application filed by Hyal Pharmaceutical Corp filed Critical Hyal Pharmaceutical Corp

1995-03-27 Priority to CA 2145605 priority Critical patent/CA2145605A1/fr

1995-08-11 Priority to JP8508371A priority patent/JPH10504828A/ja

1995-08-11 Priority to HU9701507A priority patent/HUT76846A/hu

1995-08-11 Priority to EP95927605A priority patent/EP0778776A1/fr

1995-08-11 Priority to AU31595/95A priority patent/AU3159595A/en

1995-08-11 Priority to IL11491495A priority patent/IL114914A0/xx

1995-08-11 Priority to KR1019970701164A priority patent/KR970705401A/ko

1995-08-11 Priority to PCT/CA1995/000477 priority patent/WO1996006622A1/fr

1995-08-14 Priority to APAP/P/1995/000756A priority patent/AP618A/en

1995-08-29 Priority to CN95116995A priority patent/CN1130532A/zh

1996-09-28 Publication of CA2145605A1 publication Critical patent/CA2145605A1/fr

Status Abandoned legal-status Critical Current

Links

230000000694 effects Effects 0.000 title claims abstract description 37
230000001413 cellular effect Effects 0.000 title claims abstract description 27
229920002674 hyaluronan Polymers 0.000 claims abstract description 186
229960003160 hyaluronic acid Drugs 0.000 claims abstract description 179
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 173
108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims abstract description 46
102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims abstract description 46
229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 30
229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 30
YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 30
238000000034 method Methods 0.000 claims abstract description 28
150000003839 salts Chemical class 0.000 claims abstract description 20
231100000252 nontoxic Toxicity 0.000 claims abstract description 18
230000003000 nontoxic effect Effects 0.000 claims abstract description 18
101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims abstract description 15
102100032912 CD44 antigen Human genes 0.000 claims abstract description 14
150000002148 esters Chemical class 0.000 claims abstract description 14
239000012634 fragment Substances 0.000 claims abstract description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
-1 HARLEC Proteins 0.000 claims abstract description 9
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 9
239000008223 sterile water Substances 0.000 claims abstract description 9
102100027735 Hyaluronan mediated motility receptor Human genes 0.000 claims abstract 4
108010003425 hyaluronan-mediated motility receptor Proteins 0.000 claims abstract 4
229940124531 pharmaceutical excipient Drugs 0.000 claims abstract 3
239000003814 drug Substances 0.000 claims description 45
229940079593 drug Drugs 0.000 claims description 34
230000027455 binding Effects 0.000 claims description 29
238000011282 treatment Methods 0.000 claims description 27
108020003175 receptors Proteins 0.000 claims description 24
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 20
201000010099 disease Diseases 0.000 claims description 20
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 16
239000003795 chemical substances by application Substances 0.000 claims description 13
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 12
230000000699 topical effect Effects 0.000 claims description 11
239000003242 anti bacterial agent Substances 0.000 claims description 10
FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 claims description 10
239000002246 antineoplastic agent Substances 0.000 claims description 9
239000008194 pharmaceutical composition Substances 0.000 claims description 9
229960000905 indomethacin Drugs 0.000 claims description 8
229940124597 therapeutic agent Drugs 0.000 claims description 7
239000006071 cream Substances 0.000 claims description 6
230000002792 vascular Effects 0.000 claims description 6
108010036941 Cyclosporins Proteins 0.000 claims description 5
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 5
241000792859 Enema Species 0.000 claims description 5
229940123457 Free radical scavenger Drugs 0.000 claims description 5
208000010159 IgA glomerulonephritis Diseases 0.000 claims description 5
206010021263 IgA nephropathy Diseases 0.000 claims description 5
102000000588 Interleukin-2 Human genes 0.000 claims description 5
108010002350 Interleukin-2 Proteins 0.000 claims description 5
ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 claims description 5
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 5
229930003268 Vitamin C Natural products 0.000 claims description 5
230000000202 analgesic effect Effects 0.000 claims description 5
239000003945 anionic surfactant Substances 0.000 claims description 5
229940088710 antibiotic agent Drugs 0.000 claims description 5
229940121375 antifungal agent Drugs 0.000 claims description 5
239000003429 antifungal agent Substances 0.000 claims description 5
239000003443 antiviral agent Substances 0.000 claims description 5
235000010323 ascorbic acid Nutrition 0.000 claims description 5
239000011668 ascorbic acid Substances 0.000 claims description 5
229960005070 ascorbic acid Drugs 0.000 claims description 5
229960000686 benzalkonium chloride Drugs 0.000 claims description 5
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 5
229940124630 bronchodilator Drugs 0.000 claims description 5
239000003093 cationic surfactant Substances 0.000 claims description 5
YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims description 5
229960001927 cetylpyridinium chloride Drugs 0.000 claims description 5
239000003433 contraceptive agent Substances 0.000 claims description 5
230000002254 contraceptive effect Effects 0.000 claims description 5
229930182912 cyclosporin Natural products 0.000 claims description 5
229940127089 cytotoxic agent Drugs 0.000 claims description 5
206010012601 diabetes mellitus Diseases 0.000 claims description 5
239000002934 diuretic Substances 0.000 claims description 5
229940030606 diuretics Drugs 0.000 claims description 5
239000007920 enema Substances 0.000 claims description 5
229940095399 enema Drugs 0.000 claims description 5
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 5
229960003883 furosemide Drugs 0.000 claims description 5
230000003779 hair growth Effects 0.000 claims description 5
229960003444 immunosuppressant agent Drugs 0.000 claims description 5
239000003018 immunosuppressive agent Substances 0.000 claims description 5
229940079322 interferon Drugs 0.000 claims description 5
208000028867 ischemia Diseases 0.000 claims description 5
229960004752 ketorolac Drugs 0.000 claims description 5
OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims description 5
229960003632 minoxidil Drugs 0.000 claims description 5
229960002009 naproxen Drugs 0.000 claims description 5
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 5
239000002736 nonionic surfactant Substances 0.000 claims description 5
229940087419 nonoxynol-9 Drugs 0.000 claims description 5
229920004918 nonoxynol-9 Polymers 0.000 claims description 5
239000002516 radical scavenger Substances 0.000 claims description 5
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 5
235000019154 vitamin C Nutrition 0.000 claims description 5
239000011718 vitamin C Substances 0.000 claims description 5
239000000203 mixture Substances 0.000 claims description 4
230000003637 steroidlike Effects 0.000 claims description 4
229940124599 anti-inflammatory drug Drugs 0.000 claims 2
241000722985 Fidia Species 0.000 abstract description 6
206010028980 Neoplasm Diseases 0.000 description 41
210000004027 cell Anatomy 0.000 description 33
210000001519 tissue Anatomy 0.000 description 31
241000700159 Rattus Species 0.000 description 26
210000004185 liver Anatomy 0.000 description 26
238000010186 staining Methods 0.000 description 24
102000005962 receptors Human genes 0.000 description 23
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 19
239000002953 phosphate buffered saline Substances 0.000 description 19
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 16
108010003272 Hyaluronate lyase Proteins 0.000 description 14
102000001974 Hyaluronidases Human genes 0.000 description 14
229960002773 hyaluronidase Drugs 0.000 description 14
210000002889 endothelial cell Anatomy 0.000 description 13
230000005764 inhibitory process Effects 0.000 description 11
238000002347 injection Methods 0.000 description 9
239000007924 injection Substances 0.000 description 9
239000002609 medium Substances 0.000 description 9
229960002685 biotin Drugs 0.000 description 8
235000020958 biotin Nutrition 0.000 description 8
239000011616 biotin Substances 0.000 description 8
150000004676 glycans Chemical class 0.000 description 8
239000000463 material Substances 0.000 description 8
229920001282 polysaccharide Polymers 0.000 description 8
239000005017 polysaccharide Substances 0.000 description 8
102000004169 proteins and genes Human genes 0.000 description 8
108090000623 proteins and genes Proteins 0.000 description 8
241001465754 Metazoa Species 0.000 description 7
KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 7
229940099552 hyaluronan Drugs 0.000 description 7
238000010253 intravenous injection Methods 0.000 description 7
210000002966 serum Anatomy 0.000 description 7
238000005406 washing Methods 0.000 description 7
241000283707 Capra Species 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
238000011532 immunohistochemical staining Methods 0.000 description 6
238000002372 labelling Methods 0.000 description 6
230000002265 prevention Effects 0.000 description 6
239000000243 solution Substances 0.000 description 6
241000709661 Enterovirus Species 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
210000003038 endothelium Anatomy 0.000 description 5
239000000499 gel Substances 0.000 description 5
239000011521 glass Substances 0.000 description 5
210000003491 skin Anatomy 0.000 description 5
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Chemical compound OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
102000004506 Blood Proteins Human genes 0.000 description 4
108010017384 Blood Proteins Proteins 0.000 description 4
108010001857 Cell Surface Receptors Proteins 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
229960001138 acetylsalicylic acid Drugs 0.000 description 4
230000008033 biological extinction Effects 0.000 description 4
239000000872 buffer Substances 0.000 description 4
230000006378 damage Effects 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
238000011534 incubation Methods 0.000 description 4
210000000265 leukocyte Anatomy 0.000 description 4
102000006240 membrane receptors Human genes 0.000 description 4
210000004877 mucosa Anatomy 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
238000011084 recovery Methods 0.000 description 4
230000004044 response Effects 0.000 description 4
239000000126 substance Substances 0.000 description 4
108090001008 Avidin Proteins 0.000 description 3
206010009944 Colon cancer Diseases 0.000 description 3
102000003992 Peroxidases Human genes 0.000 description 3
101000599859 Rattus norvegicus Intercellular adhesion molecule 1 Proteins 0.000 description 3
208000006011 Stroke Diseases 0.000 description 3
229910052770 Uranium Inorganic materials 0.000 description 3
239000000061 acid fraction Substances 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
238000009826 distribution Methods 0.000 description 3
230000003511 endothelial effect Effects 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
210000003141 lower extremity Anatomy 0.000 description 3
108040007629 peroxidase activity proteins Proteins 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
159000000000 sodium salts Chemical class 0.000 description 3
210000000952 spleen Anatomy 0.000 description 3
WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 2
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
OXEUETBFKVCRNP-UHFFFAOYSA-N 9-ethyl-3-carbazolamine Chemical compound NC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 OXEUETBFKVCRNP-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000271566 Aves Species 0.000 description 2
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
229920002683 Glycosaminoglycan Polymers 0.000 description 2
241000430519 Human rhinovirus sp. Species 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
239000012979 RPMI medium Substances 0.000 description 2
241000187747 Streptomyces Species 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
208000038016 acute inflammation Diseases 0.000 description 2
230000006022 acute inflammation Effects 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
102000023732 binding proteins Human genes 0.000 description 2
108091008324 binding proteins Proteins 0.000 description 2
230000037396 body weight Effects 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
208000037976 chronic inflammation Diseases 0.000 description 2
230000006020 chronic inflammation Effects 0.000 description 2
208000029742 colonic neoplasm Diseases 0.000 description 2
210000004087 cornea Anatomy 0.000 description 2
229960001760 dimethyl sulfoxide Drugs 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
229960002442 glucosamine Drugs 0.000 description 2
229940097043 glucuronic acid Drugs 0.000 description 2
229910001385 heavy metal Inorganic materials 0.000 description 2
230000001744 histochemical effect Effects 0.000 description 2
229940014041 hyaluronate Drugs 0.000 description 2
238000003364 immunohistochemistry Methods 0.000 description 2
238000012744 immunostaining Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
229910052742 iron Inorganic materials 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
230000004807 localization Effects 0.000 description 2
201000006512 mast cell neoplasm Diseases 0.000 description 2
208000006971 mastocytoma Diseases 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
235000019799 monosodium phosphate Nutrition 0.000 description 2
230000004899 motility Effects 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
229950006780 n-acetylglucosamine Drugs 0.000 description 2
201000009240 nasopharyngitis Diseases 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
229950000964 pepstatin Drugs 0.000 description 2
108010091212 pepstatin Proteins 0.000 description 2
FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 2
230000008569 process Effects 0.000 description 2
239000000700 radioactive tracer Substances 0.000 description 2
230000010837 receptor-mediated endocytosis Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
230000008685 targeting Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000008733 trauma Effects 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
230000007306 turnover Effects 0.000 description 2
238000005303 weighing Methods 0.000 description 2
HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
241000282709 Aotus trivirgatus Species 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
241000501458 Cultus Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
241000405147 Hermes Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
108010013214 Hyaluronan Receptors Proteins 0.000 description 1
102000018866 Hyaluronan Receptors Human genes 0.000 description 1
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
239000007836 KH2PO4 Substances 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
206010061137 Ocular toxicity Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
102000016979 Other receptors Human genes 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
239000012506 Sephacryl® Substances 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
206010044245 Toxic optic neuropathy Diseases 0.000 description 1
101710162629 Trypsin inhibitor Proteins 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
210000002159 anterior chamber Anatomy 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
210000001742 aqueous humor Anatomy 0.000 description 1
229910052785 arsenic Inorganic materials 0.000 description 1
RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000005388 borosilicate glass Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000003183 carcinogenic agent Substances 0.000 description 1
210000000845 cartilage Anatomy 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
210000003161 choroid Anatomy 0.000 description 1
238000011210 chromatographic step Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
210000000399 corneal endothelial cell Anatomy 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
210000000695 crystalline len Anatomy 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
229960001259 diclofenac Drugs 0.000 description 1
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
230000029087 digestion Effects 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
235000019800 disodium phosphate Nutrition 0.000 description 1
230000009429 distress Effects 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
210000003560 epithelium corneal Anatomy 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
238000001641 gel filtration chromatography Methods 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
239000003292 glue Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
238000003119 immunoblot Methods 0.000 description 1
238000002991 immunohistochemical analysis Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
210000000554 iris Anatomy 0.000 description 1
210000001865 kupffer cell Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
231100000327 ocular toxicity Toxicity 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
238000002559 palpation Methods 0.000 description 1
210000004738 parenchymal cell Anatomy 0.000 description 1
239000002245 particle Substances 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
238000009781 safety test method Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
241000894007 species Species 0.000 description 1
230000003068 static effect Effects 0.000 description 1
239000000758 substrate Substances 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
230000002992 thymic effect Effects 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
230000032258 transport Effects 0.000 description 1
229940108519 trasylol Drugs 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA 2145605 1991-07-03 1995-03-27 Modulation de l'activite cellulaire Abandoned CA2145605A1 (fr)

Priority Applications (10)

Application Number	Priority Date	Filing Date	Title
CA 2145605 CA2145605A1 (fr)	1995-03-27	1995-03-27	Modulation de l'activite cellulaire
JP8508371A JPH10504828A (ja)	1994-08-30	1995-08-11	細胞活性調整のためのヒアルロン酸およびその誘導体
HU9701507A HUT76846A (en)	1994-08-30	1995-08-11	Hyaluronic acid and derivatives for modulation of cellular activity
EP95927605A EP0778776A1 (fr)	1994-08-30	1995-08-11	Acide hyaluronique et derives destines a la modulation de l'activite cellulaire
AU31595/95A AU3159595A (en)	1994-08-30	1995-08-11	Hyaluronic acid and derivatives for modulation of cellular activity
IL11491495A IL114914A0 (en)	1994-08-30	1995-08-11	Modulation of cellular activity
KR1019970701164A KR970705401A (ko)	1994-08-30	1995-08-11	세포활성의 조정용 히알루론산과 그 유도체(hyaluronic acid and derivatives for modulation of cellular activity)
PCT/CA1995/000477 WO1996006622A1 (fr)	1991-07-03	1995-08-11	Acide hyaluronique et derives destines a la modulation de l'activite cellulaire
APAP/P/1995/000756A AP618A (en)	1994-08-30	1995-08-14	Modulation of cellular activity by administering a form of hyaluronic acid.
CN95116995A CN1130532A (zh)	1994-08-30	1995-08-29	细胞活性调节

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA 2145605 CA2145605A1 (fr)	1995-03-27	1995-03-27	Modulation de l'activite cellulaire

Publications (1)

Publication Number	Publication Date
CA2145605A1 true CA2145605A1 (fr)	1996-09-28

Family

ID=4155510

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2145605 Abandoned CA2145605A1 (fr)	1991-07-03	1995-03-27	Modulation de l'activite cellulaire

Country Status (1)

Country	Link
CA (1)	CA2145605A1 (fr)

1995
- 1995-03-27 CA CA 2145605 patent/CA2145605A1/fr not_active Abandoned

Legal Events

Date	Code	Title	Description
1996-03-22	EEER	Examination request
1999-11-05	FZDE	Dead

Publication	Publication Date	Title
AP618A (en)	1997-10-10	Modulation of cellular activity by administering a form of hyaluronic acid.
CA2122519C (fr)	2001-02-20	Traitement du cancer et prevention des metastases
Dodane et al.	1998	Pharmaceutical applications of chitosan
Liao et al.	2005	Hyaluronan: pharmaceutical characterization and drug delivery
US5614506A (en)	1997-03-25	Use of hyaluronic acid and forms to prevent arterial restenosis
US20110124596A1 (en)	2011-05-26	Composition for treating inflammatory diseases
JP2011505369A (ja)	2011-02-24	薬剤の持続送達のための多糖ゲル組成物および方法
WO1998017320A1 (fr)	1998-04-30	Utilisation de hyaluronan dans la therapie genique
US5674857A (en)	1997-10-07	Use of hyaluronic acid to repair ischemia reperfusion damage
CA2175282A1 (fr)	1997-10-30	Utilisation de diverses formes d'acide hyaluronique (ah) pour le traitement du cancer
CA2094203A1 (fr)	1994-10-17	Inhibition de l'angiogenese
US5847002A (en)	1998-12-08	Compositions, for inhibition, control and regression of angiogenesis, containing hyaluronic acid and NSAID
KR100476782B1 (ko)	2005-07-18	히알루론산수용체결합물질과이의용도
CA2156013A1 (fr)	1997-02-15	Modulation de l'activite cellulaire
Gustafson et al.	1995	Accessible hyaluronan receptors identical to ICAM-1 in mouse mast-cell tumours
JPH10287570A (ja)	1998-10-27	角膜障害症治癒促進剤
US5817644A (en)	1998-10-06	Targeting of dosages of medicine and therapeutic agents
AP448A (en)	1996-01-18	Use of hyaluronic acid and forms to prevent arterial restenosis.
CA2145605A1 (fr)	1996-09-28	Modulation de l'activite cellulaire
JPH10506884A (ja)	1998-07-07	マクロファージ浸潤に関連する病気あるいは容体、特に脳卒中、心筋梗塞の治療
JP2000513707A (ja)	2000-10-17	投与薬剤の目標化、治療薬および他のグリコサミノグリカン（ｇａｇｓ）
CA2164260C (fr)	2001-10-09	Methode de ciblage pour medicaments et agents therapeutiques
JP2024502825A (ja)	2024-01-23	抗体の局所的延長放出
CA2131130A1 (fr)	1996-03-01	Modulation de l'activite cellulaire
JP2008519032A (ja)	2008-06-05	Ｆｇｆ−２０の調合物、生成方法および使用